Clinical Trials Logo

Clinical Trial Summary

Progress in the diagnosis of infectious pathogens depends on the development of effective methods and the discovery of suitable biomarkers. There are several kinds of methods that have been used in diagnosis of various pathogens, such as microscopic examination, culture, serologic diagnosis or molecular approaches, etc. However, these methods have similar limitations, that is, the single detection of reagents. More importantly, physicians seldom consider infections with rare pathogens. Recently developed metagenomic next-generation sequencing (mNGS) has the capability to overcome limitations of traditional diagnostic tests. This new technology could identify all pathogens directly from sample with a single run in a hypothesis-free and culture-independent manner. Studies have shown that mNGS is more sensitive than traditional culture method in clinical conditions such as blood stream, respiratory and general infections. More importantly, due to unbiased sampling, mNGS is theoretically able to identify not only known but also unexpected pathogens or even discovery novel organisms. It should be noted that mNGS also has some limitations such as human genome contamination and possibly environmental microbial contamination. The vast majority of reads in mNGS are derived from human host. This would impede the overall analytical sensitivity of mNGS for pathogen detection. Host depletion methods or targeted sequencing may help to partially mitigate this disadvantage. As mNGS could not, by itself, define whether the detected microbe is the causative pathogen or environmental microorganism, a multidisciplinary discussion by clinicians, microbiologists as well as the lab technicians is required to interpret the result.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05353634
Study type Observational
Source Liaocheng People's Hospital
Contact
Status Completed
Phase
Start date June 10, 2020
Completion date April 20, 2022

See also
  Status Clinical Trial Phase
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Terminated NCT00511186 - A Study in Sepsis Patients With Renal Failure Phase 2
Completed NCT00509938 - Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients Phase 1/Phase 2
Completed NCT00210938 - Doripenem in the Treatment of Complicated Intra-Abdominal Infections Phase 3
Completed NCT00229060 - Doripenem in the Treatment of Complicated Intra-Abdominal Infections Phase 3
Completed NCT01781182 - Infant Antibiotic Resistance and Implications for Therapeutic Decision-making N/A
Completed NCT02155114 - Iron Homoeostasis in Inflammation N/A
Completed NCT02079298 - Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants Phase 4